Press release – For immediate release – 5:45 pm CEST
Disclosure of total number of voting rights and number of shares in the capital as of May 31, 2026, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
| Total number of shares | 38,202,387 |
| Number of real voting rights* (excluding treasury shares**) | 38,143,292 |
| Theoretical number of voting rights* (including treasury shares**) | 38,179,187 |
(**) pursuant to article 223-11 of the AMF’s General Regulations
Furthermore, as of May 27, 2026, out of the 14,424,541 warrants (BSA) issued in connection with the 2025 capital increase, 12,325,725 remained outstanding and exercisable.
Pioneering innovative imaging services and Software as a Medical Device, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit